JWS Consulting is a division of Johnson Winter & Slattery providing commercial consulting services.
We are engaged by major Australian and international corporations as legal counsel on their business activities, disputes and most challenging matters.
Established in 1993 by Tony Johnson, Nigel Winter and Peter Slattery as a boutique corporate firm, JWS grew rapidly to become a leading independent Australian firm.
The quality of our legal advice and service to clients is recognised through independent industry recognition and direct client feedback.
Learn more about breaking news at Johnson Winter & Slattery, including major transaction announcements, practitioner appointments and team expansions.
JWS supports a number of community initiatives and not for profit organisations across Australia through pro bono legal work and charitable donations.
We are proud to sponsor a number of community initiatives.
Clare specialises in corporate and public securities law, with a particular focus on equity capital markets.
She has experience in cross-border and domestic corporate transactions including advising on equity and hybrid security fundraisings, regulated and private M&A, business sales and acquisitions, restructures, securities regulatory and ASX compliance issues, ESOPs and other general corporate matters.
She regularly acts for companies and investors in the healthcare and biotechnology sector, as well as the technology industry more broadly.
Advised on its A$33.3 million IPO and ASX listing in March 2017.
Advised on its A$36.5 million IPO and ASX listing in 2015 and its follow-on capital raisings in 2016 and 2017.
Advised on its private placement of CDIs and Security Purchase Plan in 2016.
Advised on A$75 million placement and Share Purchase Plan in 2016.
Advised on its investment in ASX-listed Southern Cross Goldfields in November 2014.
Advised on its underwritten entitlement offer in 2014.
Advised on its bridge financing in 2017.
Advised on its investment in OneConfig in 2016.
Advised on its investment in Renew Medical in 2016.
Advised on its investment in RangeMe and related redomicile in 2015.
Advised on its investment in Cardiac Dimensions in 2014.
Advised on its Series C investment in Spinifex Pharmaceuticals and Spinifex’s related redomicile in 2014.
Advised on infant formula joint venture with Bega Cheese in 2016.
Advised on redomicile to Bermuda via scheme of arrangement in 2015.
Acted as Australian counsel on acquisition of Transaction Services Group in 2015.
Advised on acquisition of the LCR Group in 2014.
Advised on acquisition of Yuruware in 2014.
Acted as Australian counsel on the acquisition of Nokia Australia 2014.
Advised on implementation of its management incentive plan.
Advice on equity incentive plans.
Generally, foreign companies offering securities in Australia need to comply with the prospectus provisions in the Corporations Act 2001 (Cth) (the Act). However, in addition to the normal...
Find out why ASX can be an effective prelude to a future listing in the US.